Hemophilia: Where are we today?

Larry J Smith; Donna D Castellone; Michael A Nardi

doi:10.29074/ascls.118.001271

This article requires a subscription to view the full text. If you have a subscription you may use the login form below to view the article. Access to this article can also be purchased.

Larry J Smith1,4
Donna D Castellone2
Michael A Nardi3

¹ Abbott Diagnostic Division - Hematology;
² New York Presbyterian - Columbia Medical Center;
³ New York University School of Medicine

↵* Corresponding author; email: larry.smith{at}abbott.com

Abstract

Hemophilia is a rare congenital bleeding disorder characterized by decreased levels of coagulation factor VIII or factor IX in the circulation. The disorder is associated with lifelong bleeding that ranges from mild to severe in affected individuals. Treatment requires replacement of the missing factor and is often associated with the development of antibodies that may exacerbate the bleeding diathesis seen in these individuals. The clinical laboratory plays a unique role in the diagnosis of hemophilia and in monitoring the effectiveness of standard replacement therapy, as well as many of the newer replacement therapies that have been developed.